CrystalGenomics

Seongnam-si, South Korea Founded: 2000 • Age: 26 yrs
Clinical stage pharmacy company focused on the novel drugs in areas of inflammation, oncology, and infectious disease
Request Access

About CrystalGenomics

CrystalGenomics is a company based in Seongnam-si (South Korea) founded in 2000.. The company has 80 employees as of December 31, 2024.

  • Headquarter Seongnam-si, South Korea
  • Employees 80 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Cg Invites Co., Ltd.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $4.92 M (USD)
    48.67
    as on Dec 31, 2024
  • Net Profit
    $-34.95 M (USD)
    -5.36
    as on Dec 31, 2024
  • EBITDA
    $-23.46 M (USD)
    -13.22
    as on Dec 31, 2024
  • Latest Funding Round
    $851.6 K (USD), Post-IPO

    Dec 23, 2015

  • Investors
  • Employee Count
    80

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of CrystalGenomics

CrystalGenomics is a publicly listed company on the KRX with ticker symbol 083790 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: KRX · Ticker: 083790 . Sector: Health technology · South Korea

Funding Insights of CrystalGenomics

  • Total Funding
  • Total Rounds 3
  • Last Round Post-IPO — $851,600
  • First Round

    (13 Jan 2012)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2015 Amount Post-IPO - CrystalGenomics Valuation

investors

Jun, 2014 Amount Post-IPO - CrystalGenomics Valuation

investors

Jan, 2012 Amount Post-IPO - CrystalGenomics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in CrystalGenomics

CrystalGenomics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Ministry of Health and Welfare and Korea-Seoul Life Science Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
Government entity responsible for health and welfare services in Taiwan.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by CrystalGenomics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - CrystalGenomics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Crystalgenomics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of CrystalGenomics

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Crystalgenomics

Frequently Asked Questions about CrystalGenomics

When was CrystalGenomics founded?

CrystalGenomics was founded in 2000 and raised its 1st funding round 12 years after it was founded.

Where is CrystalGenomics located?

CrystalGenomics is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.

How many employees does CrystalGenomics have?

As of Dec 31, 2024, the latest employee count at CrystalGenomics is 80.

What is the annual revenue of CrystalGenomics?

Annual revenue of CrystalGenomics is $4.92M as on Dec 31, 2024.

What does CrystalGenomics do?

Crystal Genomics is a clinical stage biopharmaceutical company working on the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases.The Companys lead therapeutic program is Accelex, a next-generation NSAID for osteoarthritis is in NDA approval phase. Other products include CG400549 the antibiotic for MRSA and CG200745, a molecular targeted cancer therapeutic for solid tumors are in phase 2 development. Another molecular targeted cancer therapeutic CG026806 is in pre-clinical trials. It acquired Hwail Pharmaceutical on August 14, 2013 and has partnered with Daewoong Pharmaceutical for Acelex Commercialization in Korea. It also offers platform technology for drug discovery.

Is CrystalGenomics publicly traded?

Yes, CrystalGenomics is publicly traded on KRX under the ticker symbol 083790.

Who are CrystalGenomics's investors?

CrystalGenomics has 2 investors. Key investors include Ministry of Health and Welfare, and Korea-Seoul Life Science Fund.

What is CrystalGenomics's ticker symbol?

The ticker symbol of CrystalGenomics is 083790 on KRX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available